Total Payments
$429,194
2024 Payments
$31,247
Companies
27
Transactions
171
Medicare Patients
413
Medicare Billing
$55,498
Payment Breakdown by Category
Consulting$378,995 (88.3%)
Travel$22,906 (5.3%)
Research$21,450 (5.0%)
Other$3,220 (0.8%)
Food & Beverage$2,624 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $378,995 | 97 | 88.3% |
| Travel and Lodging | $22,906 | 35 | 5.3% |
| Unspecified | $21,450 | 2 | 5.0% |
| Honoraria | $3,000 | 1 | 0.7% |
| Food and Beverage | $2,624 | 35 | 0.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $220.00 | 1 | 0.1% |
Payments by Type
General
$407,744
169 transactions
Research
$21,450
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $133,142 | 9 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $87,590 | 48 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $46,595 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $33,728 | 14 | $0 (2024) |
| Daiichi Sankyo Inc. | $32,728 | 19 | $0 (2024) |
| AstraZeneca UK Limited | $29,227 | 18 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $16,806 | 14 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $7,700 | 1 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $5,800 | 3 | $0 (2023) |
| Sumitomo Pharma America, Inc. | $4,731 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,247 | 10 | AstraZeneca Pharmaceuticals LP ($11,897) |
| 2023 | $58,264 | 29 | AstraZeneca Pharmaceuticals LP ($14,656) |
| 2022 | $45,011 | 17 | Takeda Pharmaceuticals U.S.A., Inc. ($21,288) |
| 2021 | $33,406 | 16 | AstraZeneca UK Limited ($11,531) |
| 2020 | $95,818 | 17 | E.R. Squibb & Sons, L.L.C. ($45,420) |
| 2019 | $33,394 | 46 | E.R. Squibb & Sons, L.L.C. ($24,043) |
| 2018 | $105,531 | 13 | PFIZER INC. ($98,189) |
| 2017 | $26,523 | 23 | Daiichi Sankyo Inc. ($15,178) |
All Payment Transactions
171 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | SOBI, INC | KINERET (Drug) | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $117.63 | General |
| Category: Not Applicable | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 06/25/2024 | Immunocore Limited | KIMMTRAK (Drug) | Consulting Fee | Cash or cash equivalent | $2,888.00 | General |
| Category: Oncology | ||||||
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $7,786.50 | General |
| Category: Oncology | ||||||
| 01/01/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 12/14/2023 | Deciphera Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/01/2023 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $5,101.50 | General |
| Category: Oncology | ||||||
| 11/22/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 11/10/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/17/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/06/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $4,452.50 | General |
| Category: Oncology | ||||||
| 08/03/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,222.00 | General |
| Category: Oncology | ||||||
| 07/18/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 07/18/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 07/11/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF TAK-105 IN HEALTHY ADULTS | Takeda Pharmaceuticals U.S.A., Inc. | $21,450 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 121 | 251 | $125,702 | $21,138 |
| 2022 | 6 | 138 | 182 | $128,523 | $20,518 |
| 2021 | 3 | 59 | 65 | $21,664 | $5,013 |
| 2020 | 5 | 95 | 102 | $39,200 | $8,829 |
Total Patients
413
Total Services
600
Medicare Billing
$55,498
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 86 | $66,478 | $10,975 | 16.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 39 | $21,489 | $4,067 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $20,615 | $3,082 | 15.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 34 | 107 | $17,120 | $3,013 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 39 | 39 | $42,315 | $6,302 | 14.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 59 | $32,509 | $5,447 | 16.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 36 | $27,828 | $4,614 | 16.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $18,139 | $2,885 | 15.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 12 | $4,692 | $723.50 | 15.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 13 | 19 | $3,040 | $546.06 | 18.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 31 | 37 | $11,766 | $2,399 | 20.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $4,173 | $1,353 | 32.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 15 | 15 | $5,725 | $1,262 | 22.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 41 | 45 | $13,761 | $2,522 | 18.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $5,192 | $1,746 | 33.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 19 | 22 | $9,215 | $1,682 | 18.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $7,180 | $1,586 | 22.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 12 | $3,852 | $1,293 | 33.6% |
About Dr. Javid Moslehi, MD
Dr. Javid Moslehi, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538123716.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Javid Moslehi, MD has received a total of $429,194 in payments from pharmaceutical and medical device companies, with $31,247 received in 2024. These payments were reported across 171 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($378,995).
As a Medicare-enrolled provider, Moslehi has provided services to 413 Medicare beneficiaries, totaling 600 services with total Medicare billing of $55,498. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease
- Location San Francisco, CA
- Active Since 04/14/2006
- Last Updated 01/24/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1538123716
Products in Payments
- BAVENCIO (Drug) $124,767
- OPDIVO (Biological) $30,609
- LUMOXITI (Biological) $19,045
- Savaysa (Drug) $15,178
- CALQUENCE (Drug) $14,720
- KISQALI (Drug) $13,806
- LYNPARZA (Drug) $10,700
- ORGOVYX (Drug) $8,051
- Nubeqa (Drug) $7,700
- ICLUSIG (Drug) $7,515
- IMBRUVICA (Drug) $6,088
- BOSULIF (Drug) $5,338
- BRUKINSA (Drug) $4,550
- KIMMTRAK (Drug) $2,888
- KINERET (Drug) $2,870
- CELLEX (Device) $2,640
- QINLOCK (Drug) $2,500
- JARDIANCE (Drug) $1,740
- SPRYCEL (Drug) $1,650
- ELIQUIS (Drug) $1,560
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736